Three decades of pharmaceutical research, spanning fundamental biochemistry, drug discovery, bioanalytical method development, and regulatory science — with proven contributions to programs that reached patients.
Antecello Pharma supports clients across a broad spectrum of molecular classes and therapeutic areas, grounded in decades of hands-on laboratory and program leadership experience.
Foundational research on microsomal triglyceride transfer protein (MTP), apolipoprotein B assembly, and atherogenic lipoprotein regulation — work that helped enable a marketed therapy for hyperlipidemia.
Cross-modality experience covering small molecule discovery, therapeutic peptides, and biologics — including monoclonal antibodies and complex protein therapeutics from preclinical through clinical phases.
Assay design and validation for pharmacokinetics (PK), anti-drug antibody (ADA), and toxicology samples in both preclinical and clinical settings — built on GLP-compliant frameworks.
Direct authorship and review experience across IND, NDA, ANDA, and BLA submissions — including three INDs filed at Bristol-Myers Squibb and one BLA at NeoPharm.
Supported the development and FDA approval of sixteen generic products at Fresenius Kabi — covering bioequivalence, stability, manufacturing scale-up, and regulatory submission.
End-to-end coordination of Chemistry, Manufacturing, and Controls activities — from early formulation through commercial launch, on time and within budget across thirty plus client engagements.
Years of collaborative research at Bristol-Myers Squibb on microsomal triglyceride transfer protein inhibitors contributed to the eventual development of lomitapide (marketed as Juxtapid by Aegerion Pharmaceuticals) — a therapy approved for patients with homozygous familial hypercholesterolemia.
This translational journey, from foundational biochemistry papers in the late 1990s to a real treatment helping patients with a rare and serious condition, reflects the kind of rigorous, end-to-end scientific work Antecello Pharma brings to client engagements today.
A snapshot of representative scientific programs and contributions across a thirty plus year career — from fundamental protein biochemistry at academic and pharma research institutes to applied drug development and bioanalytical leadership.
Played a central role in the characterization of microsomal triglyceride transfer protein and the discovery and biochemical evaluation of MTP inhibitors — research that helped lay the groundwork for lomitapide (Juxtapid), now marketed for homozygous familial hypercholesterolemia.
Led biologics and bioanalytical departments at Charles River, SGS, and NanoInk. Designed and validated more than fifty PK, ADA, and toxicity assays supporting preclinical studies and clinical trial sample analysis.
Established a new GMP-compliant analytical laboratory from the ground up — qualifying equipment, authoring standard operating procedures, and recruiting and training a full technical staff to support client programs.
Led analytical assay development and validation supporting manufacturing, stability testing, and FDA submission for sixteen generic products, contributing to their successful market launches.
Delivered project management support across more than thirty programs at Baxter, ThermoFisher, AbbVie, Ovation, and NeoPharm — coordinating CMC activities, budgets, and cross-functional teams to consistent on-time, on-budget completion.
Current consulting practice supporting pharma and biotech clients with feasibility, IND-enabling program design, CRO/CMO selection and oversight, and regulatory document review for IND, NDA, ANDA, and BLA filings.
A selection of peer-reviewed research contributions across protein biochemistry, lipid metabolism, and pharmaceutical sciences. For a comprehensive list, please visit Dr. Jamil's LinkedIn profile.
From early phase study design to bioanalytical method development and regulatory filings — Antecello Pharma brings hands-on expertise to every engagement.
Get in Touch